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Abstract: Double-walled nanoparticles (DWNPs), containing doxorubicin as a model drug, were
produced using poly-(D,L-lactide-co-glycolide) (PLGA) and poly(L-lactide) (PLLA) by the solvent
evaporation technique. Double-walled microparticles containing doxorubicin were also produced
to make possible the examination of the inner morphology and drug distribution using optical
and fluorescence microscopy. The produced microparticles present a double-walled structure with
doxorubicin solubilized in the PLGA-rich phase. The DWNPs produced present very low initial
burst values and a sustained DOX release for at least 90 days with release rates decreasing with the
increase in the PLLA amount. Zero-order release kinetics were obtained after day 15. The results
support that the PLLA layer acts as a rate control barrier and that the diffusion of doxorubicin from
the drug-loaded inner PLGA core can be retarded by an increase in the thickness of the unloaded
outer layer. The unloaded double-walled nanoparticles produced were used in in vitro tests with
CHO cells and demonstrate that they are nontoxic, while the double-walled nanoparticles loaded
with doxorubicin caused a great cellular viability and decreased when tested in vitro.
Keywords: drug delivery; PLGA/PLLA; double-walled nanoparticles; controlled release; doxorubicin
1. Introduction
The use of nanoparticles (NP) as drug carriers is one of the most promising areas of
human health care science since they can circulate in the blood or cross cell membranes and
be internalized [1–6]. Drugs are frequently limited by dose-limiting toxicity and, therefore,
it is important to control their release during the transportation to the site of action. NP are
an excellent system for this matter, since it is possible to easily manipulate their size and
surface characteristics, therefore, altering their behavior towards a desired goal. Controlled
release and particle degradation characteristics can be readily modulated by the choice of
matrix constituents and the concentration of loaded drug. Most of the studies published
so far were performed with a single-polymer layer NP where a high initial burst release
generally occurs, which present a limitation in clinical application. This restriction can be
overcome using particles containing two immiscible polymers that form a core (internal)
and a shell (outer) layer, commonly known as double-walled (DW) particles. Furthermore,
the use of DW particles allows the drug release rate to be tuned by choosing the suitable
core and shell polymers and adjusting the thickness of the outer layer by handling the
polymers mass ratio. This approach provides more options concerning the type of drug
release profiles intended for each type of treatment [7]. Matsumoto and co-workers found
that the phenomenon of polymer-polymer phase separation can be applied with the Poly(L-
lactide) (PLLA)/Poly(DL-lactide-co-glycolide) (PLGA) system [8], both biodegradable and
biocompatible polymers that have generated tremendous interest [9,10]. Studies using
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this system and copolymers of PLGA to produce double-walled microparticles (DWMP)
for the sustained release of doxorubicin [11], etanidazole [12–14], 5-fluorouracil [15] and
globular proteins [16–18] have been reported. In these systems, it was found that the drug is
distributed in the inner core material and the shell can act as a rate-limiting barrier to drug
release. Our group previously reported the production of double-walled nanoparticles
(DWNPs) containing meloxicam using PLLA/PLGA that can ally the benefits of a double-
layer system to those of NP [19]. While studies of drug release from double-layered particles
produced with different mass polymer ratios have been reported for microparticles, no
such studies have been conducted using nanoparticles. Therefore, the aim of the present
study is to produce drug-loaded DWNPs using PLLA and PLGA polymers with different
mass ratios to test for the possibility to achieve slower drug releases and lower initial burst
releases when compared to one-layer systems
The model drug chosen for this work is a water-soluble drug, doxorubicin (DOX),
an anthracycline used in the treatment of a wide range of cancers, including many types
of carcinomas (solid tumors). It functions by inhibiting nucleic acids synthesis within
cancer cells, but it is rapidly cleared from the blood and leads to various dose-limiting side
effects [20,21]. DWNPs were characterized in terms of morphology, size, zeta potential and
crystallinity and further used for in vitro release studies to evaluate whether a PLLA layer
surrounding a PLGA core can be used to adjust the drug release rate and for in vitro assays
in mammalian cell cultures to assess their therapeutic potential.
2. Experimental
2.1. Materials
PLLA (Mw 85,000–160,000), PLGA (50:50) (Mw 40,000–75,000), Poly(vinyl alcohol)
(PVA) (Mw 30,000–70,000; degree of hydrolysis: 87–90%) used as the emulsifying agent
and doxorubicin hydrochloride were obtained from Sigma Aldrich (Saint-Louis, MO, USA).
Dichloromethane (DCM), (99.9% purity), acetone (95% purity) and phosphate-buffered
saline (PBS) were purchased from Fluka (Buchs, Switzerland). Culture media, serum,
antibiotics and fungizone and fetal bovine trypsin, were purchased from Gibco (Grand
Island, NY, USA). All other materials or solvents used were of analytical grade. Live/Dead
viability kit and Toto-3 were achieved from Invitrogen (Grand Island, NY, USA).
2.2. Preparation of PLLA/PLGA Double-Walled Nanoparticles and PLGA Nanoparticles
PLLA/PLGA double-walled nanoparticles were prepared, utilizing the polymer in-
compatibility between PLLA and PLGA which result in their complete phase separation [8],
using the oil-in-water-in water emulsion solvent extraction/evaporation technique accord-
ing to Albuquerque et al. [19]. Briefly, PLLA and PLGA were separately dissolved in DCM
in a polymer mass ratio of PLLA to PLGA of 2:1, 4:1 and 6:1 w/w using a total polymer
quantity of 200 mg and a total DCM volume of 1 mL. The two polymeric solutions were
mixed in the vortex and subsequently added to 10 mL of an aqueous solution containing
PVA 3% w/v as a stabilizer and sonicated for 30 s at 100 W (Model UP100H, MS2, Hielscher)
to produce the first o/w emulsion. The formed o/w emulsion was poured dropwise
into 300 mL of a 0.25% (w/v) PVA aqueous solution and magnetically stirred for 24 h at
room temperature to extract/ evaporate the organic solvent and harden the particles. The
produced NP were collected by centrifugation at 13,257× g for 10 min (Sartorius, Sigma
4K15), washed three times with deionised water and freeze dried (Telstar Cryodos).
DWNPs containing DOX were prepared adding 10 mg of DOX to the polymer solution
and using the same procedure. PLGA NP-containing DOX were prepared in the same
manner using 200 mg of PLGA.
2.3. Preparation of PLLA/PLGA Double-Walled Microparticles
Double-walled microparticles were intentionally produced large enough to enable the
observation of the DOX solubilization local by microscopy. DWMPs of PLLA/PLGA mass
ratio of 2:1 were prepared using the solvent extraction/evaporation technique. A total
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polymer mass of 600 mg of PLLA and PLGA was separately dissolved in DCM in order
to get a mass ratio of these polymers of 2:1, using a total DCM volume of 3 mL. The
two polymeric solutions were mixed and 10 mg of DOX were added to this solution. This
polymeric solution was added to 800 mL of an aqueous solution of PVA 0.25% (w/v),
therefore creating an o/w emulsion, and stirred at a 1200 rpm rate for 2 h to allow DCM
evaporation and MP hardening. The produced MP were collected by centrifugation
(Sartorius, Sigma 4K15, St. Louis, MO, USA), washed with deionized water and freeze-
dried (Telstar Cryodos, Mumbai, India). To identify the double-walled structure as well as
the distribution of DOX in the particle, MP were incorporated in a resin, cross sectioned
and their surface morphology and internal structure was observed by microscopy. MP
images were taken by a digital camera Nikon DXM1200F coupled to a Zeiss Axioplan
2 Optical Microscope under a reflected-polarized normal light that allows the identification
of distinct polymeric layers. Since DOX is colored, the site of solubilization of DOX within
the loaded MP was also determined.
2.4. Characterization of NP
2.4.1. Surface Morphology
The characterization of NP morphology and estimation of NP size was performed
by Scanning Electron Microscopy (SEM). Images were obtained with a scanning electron
microscope (model DSM 962, Zeiss, Karlsruhe, Germany) with an accelerating voltage of
20 kV after gold-coating the samples fixed onto metallic studs under argon atmosphere.
2.4.2. Particles Size and Zeta Potential Analysis
The size and the zeta potential of the produced NP were measured by dynamic light
scattering (DLS) performed using a Laser Light Scattering Instrument (Zetasizer Nano
ZS, Malvern). Freeze-dried NP were dispersed in a PVA 0.5% (w/v) aqueous solution,
sonicated, washed three times with deionised water and resuspended in water before each
measurement. All measurements were made in triplicate.
2.4.3. Thermal Analysis by Differential Scanning Calorimetry (DSC)
Thermal analysis of NP was performed using a differential scanning calorimeter (Se-
taram DSC131) equipped with a thermal analysis data system connected to a cooling system.
Sealed aluminum pans containing 10 mg of sample were heated from −20 ◦C to 80 ◦C,
cooled to 25 ◦C, and reheated to 250 ◦C at a rate of 10 ◦C/min under nitrogen atmosphere.
2.4.4. Drug Encapsulation Efficiency (EE)
The amount of DOX encapsulated within the particles was determined by High Per-
formance Liquid Chromatography (HPLC) (Hitachi-Merck, Okinawa, Japan). Then, 5 mg
of particles were completely dissolved in 5 mL of DCM. The solution was then placed in
a desiccator and after complete evaporation of DCM, 2 mL of acetonitrile: acetate buffer
(pH 4) 50:50 (v/v/v) were added. The sample was then analyzed for its drug concentration
using a Merck RP-18 (Merck, Darmstadt, Germany) column eluted with a solution ace-
tonitrile:acetate buffer (pH 4) 50:50 (v/v) at a flow rate of 0.8 mL min−1. A UV detector
(Merck Hitachi, Okinawa, Japan) at a wavelength of 234 nm was used. The encapsulation
efficiency was determined as the mass ratio between the DOX amount within particles and
the quantity of DOX used in the preparation.
2.5. In Vitro DOX Release Studies
In vitro release of DOX from DWNPs and PLGA NP was conducted dispersing 10 mg
of NP in 7 mL of phosphate buffer media (PBS) at pH 7.2 in closed centrifuge tubes. The
tubes were placed at a temperature of 37 ◦C and a speed rotation of 120 rpm in a horizontal
shaker. At time intervals, the tubes were removed and centrifuged at 9000 rpm for 15 min.
The supernatants were collected and the amount of DOX released was quantified as
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described in Section 2.4.4. The precipitated NP were re-suspended in 7 mL of fresh buffer
and placed back in the incubator.
2.6. In Vitro Cell Assays
2.6.1. Cell Culture
CHO cells (Hamster Chinese Ovary, ECACC No. 85050302) were routinely propagated
in static conditions. Briefly, D-MEM culture medium (Dulbecco’s Modified Eagle Medium,
Gibco) with 4.5 g/L glucose and GlutaMAX™ and without pyruvate was supplemented
with penicillin and streptomycin, both 50 I.U/mL, and 10% (v/v) FBS. Sub-culture was
performed by trypsinization when cellular growth reached approximately 70% confluence.
Cultures were grown in solid supports at 37 ◦C in a humidified atmosphere with 5% CO2.
2.6.2. Cell Viability Assays
The effect of unloaded NP and DOX-loaded NP on cell viability was investigated
with a culture of CHO cells by counting the absolute number of cells, by flow cytometry
and by fluorescence microscopy using the Live/Dead viability kit. The experiments were
performed using PLGA NP and DWNPs in a 6:1 mass ratio. To prevent cell culture contam-
inations, NP were resuspended and washed in sterile PBS supplemented with penicillin,
streptomycin and fungizone (25 µg/mL). This suspension was kept up to 2 weeks at 4 ◦C.
• Flow Cytometry
CHO cells were seeded in D-MEM culture medium for 24 h in a CO2 incubator (5%
CO2 at 37 ◦C). After that, 100 µL of a DOX-loaded NP or unloaded NP suspension with
a concentration of 1 mg NP/mL were added to 300 µL of cell culture. An assay with
no addition of NP was also performed as a control. After 48 h, cells were collected and
resuspended in 1 mL of medium. For each sample, a calcein assay (identifying live cells),
a Toto-3 assay (identifying dead cells), an assay with both calcein and Toto-3 and an assay
with no addition were performed. Calcein was incubated at 0.2 µM for 30 min, whereas
Toto-3 was incubated for 10 min at 750 µM, both at room temperature. Flow cytometry was
performed on a CyAn ADP (Beckman Coulter, Fort Collins, CO, USA). Then, 488 nm and
642 nm lasers were used to excite calcein and Toto-3, respectively. Calcein and Toto-3 were
detected with a 530/30 and 665/20 nm bandpass filter, respectively.
• Absolute number of cells
CHO cells were seeded in DMEM culture medium for 24 h in a CO2 incubator (5%
CO2 at 37 ◦C). After that, 100 µL of a DOX-loaded NP or unloaded NP suspension with
a concentration of 1 mg NP/mL were added to 300 µL of cell culture. An assay with
no addition of NP was also performed as a control. After 48 h, cells were collected and
resuspended in 0.5 mL of medium and counted using a Scepter™ 2.0 automated cell
counter (Merck Millipore, Burlington, MA, USA) with the 40 µm sensor. The results were
analyzed using the Scepter™ software.
• Fluorescence microscopy
Cell viability was also analyzed by fluorescence microscopy using the Live/Dead
viability kit. Briefly, 100 µL of combined LIVE/DEAD assay reagents was added to CHO
cells grown in 12 mm diameter coverslips. Cells were incubated with the reagent at 37 ◦C
for 35 min. Fluorescent intensity was measured with an excitation wavelength of 550 nm
and an emission wavelength of 590 nm under the fluorescence microscope (TE2000, Nikon)
equipped with a Hamamatsu Flash 2.8 chamber and Prior Lumen 200 Pro lighting. Green
fluorescence (caused by calcein acetoxymethyl) indicates viable cells and red fluorescence
(caused by ethidium homodimer) indicates dead cells. ImageJ was used to analyze the
obtained images.
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3. Results and Discussion
3.1. Nanoparticles Characterization
The surface morphology of unloaded and DOX-loaded DWNPs produced with 2:1,
4:1 and 6:1 PLLA: PLGA mass ratios was examined by scanning electron microscopy and
representative images are presented in Figure 1. NP show a regular spherical shape and
a smooth surface (Figure 1A) that is not affected by the presence of DOX (Figure 1B).
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The existence of a double-walled structure can be observed in the DWNPs thermo-
grams (Figure 3), where two glass transition phenomena are evident at 44.9–45.75 ◦C and
at 56.4–58.65 ◦C, near the glass transition tempe atures of PLGA and PLLA, respectively,
indicating that phase separation occurred. For a miscible blend, we would observe a single
Tg between the Tg´s of the original polymers [22,23]. The glass transition temperatures
(Tg) of the original polymers PLGA and PLLA measured were 43.0 ◦C and 52.1 ◦C for
PLGA and PLLA, respectively. At 175.3 ◦C, one crystalline melting point was observed,
attributed to LLA, once PLGA is an amorphous polymer. In order to investigate the
distribution of DOX inside PLLA/PLGA NP and since NP are too small to allow cross-
sectioning, double-walled microparticles loaded with DOX were also produced, subjected
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to cross-sectioning and observed using an optical microscope (Figure 4). This technique
allows an easy identification due to the red color of doxorubicin.
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the interface between PLLA and PLGA and DOX.
In Figure 4 a shell surrounding a core may be seen confirming the formation of
double-walled microparticles where a polymer engulfs the other in a single step with the
solvent extraction/evaporation technique. PLLA/PLGA DWMP with a polymer mass
ratio of 2:1 produce a PLGA-rich inner phase and a PLLA-rich outer phase as concluded
by Albuquerque et al. [19] and other authors [8,12]. Figure 4 also shows the preferential
DOX distribution in the core, therefore, indicating that DOX has a greater affinity with
PLGA. Other groups have also verified a preferential molecule distribution between PLLA
and PLGA in DW microspheres. A similar distribution was obtained by Tan and Wang
and Lee et al. [7,13,14] that observe that DOX solubilisation local was mainly within the
PLGA-rich phase while Rahman and Mathiowitz reported that BSA was mainly located in
the PLLA-rich phase [16].
The obtained DWMP can be considered a reservoir-dispersed matrix system with
DOX solubilized in the PLGA core and the PLLA-rich shell acting as a barrier that can
control drug release. The zeta potential of DWNPs, measured at pH 7, were −13.4 ± 0.7 mV,
−12.4 ± 0.9 mV and −12.7 ± 0.4 mV, for DOX-loaded DWNPs 2:1, 4:1 and 6:1, respectively,
and −13.9 ± 0.7 mV, −12.9 ± 0.9 mV and −11.1 ± 1.4 mV, for 2:1, 4:1 and 6:1 for unloaded
DWNPs, respectively, indicating the presence of deprotonated PLGA carboxylic groups on
the outer surface of NP. These values show that NP have colloidal stability and that the
presence of DOX do not change NP superficial charge and the way these particles form
clusters as DOX is loaded inside the NP.
Regarding the EE for the particles produced, defined as the percentage of the mass of
DOX into NP relative to the amount of DOX used in DWNP preparation, a decrease was
bserved when the PLLA/PLGA mass ratio g es from 2:1 (25.6%) to 4:1 (16.3%) and to
6:1 (13.5%). This behavior can be explained by the fact that increasing the PLLA/PLGA
ratio and maintaining the total polymer mass, a smaller core volume composed of PLGA to
which DOX has affinity is available f r DOX solubilization and therefore some DOX might
be solubilized in the outer PLLA layer and can thus be lost in washing procedures during
the NP production process. The EE values obtained are lower than those reported for DW
microparticles, in the range between 31% and 87% [7,8,15,17]. This lower EE values can
be attributed to a larger loss of drug to the aqueous phase that can occur during the first
emulsification process when high sonication powers are applied. The EE obtained for DOX
(25.6%) in a PLLA/PLGA mass ratio 2:1 is similar to that reported for meloxicam-loaded
DWNPs with a PLLA/PLGA mass ratio of 1:1 (26%) [19].
Polymers 2021, 13, 3230 8 of 12
3.2. In Vitro Controlled Drug Release
To compare the release profile of doxorubicin from DWNPs with different mass ratios
of PLLA/PLGA and from monolithic PLGA NP, drug release tests were performed under
the same conditions (Figure 5). The cumulative in vitro release of DOX from DWNPs with
PLLA as the shell material and PLGA as the core material shows different profiles than
those obtained with monolithic PLGA NP, with much lower initial burst release values
and slower drug release rates. They are characterized by a very low initial burst release,
assumed to result from the diffusion of the drug located on or near the outer surface of the
DWNPs, followed by a sustained release of doxorubicin for 96 days during which different
rates depending on the release mechanisms involved [24] can be observed.
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a pure Fickian transport, for DWNP 6:1. This behavior can be explained by the lower chain
flexibility of PLLA polymer (that has a higher Tg) when compared with PLGA. After the
15th day, all NP present a zero-order release kinetic that can be due to particles erosion and
polymers degradation. During this phase and until 2 months DWNPs 2:1 and 4:1 show
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a zero-order kinetic with rates of 0.19% and 0.12% DOX release day−1, respectively, much
lower than that obtained for PLGA NP (0.43% DOX release day−1).
Table 1. Diffusion exponent n and constant k, according to Equation (1), of doxorubicin release from
DWNPs with different PLLA/PLGA mass ratios and PLGA.
Particle n n Error (%) k (day−1) k Error (%) r2
DOX–DWNP 2:1 0.58 7.6 3.28 10.6 0.99
DOX–DWNP 4:1 0.49 10.1 2.98 11.3 0.99
DOX–DWNP 6:1 0.43 2.1 1.32 4.9 0.99
PLGA NP 0.62 1.9 6.96 1.5 0.99
After 2 months, the release rates increase to 0.48% and 0.44% DOX release day−1,
similar to the value determined for PLGA. These results support that PLLA acts as
a rate-limiting barrier and strongly indicate that a non-drug-loaded outer layer can be effec-
tively used to adjust the drug release rate of DOX from the drug-loaded inner PLGA core,
therefore, allowing a zero-order kinetic release to be achieved. There are no published stud-
ies concerning drug release from double-walled nanoparticles. However, similar profiles,
exhibiting a low initial burst release followed by a characteristic lag phase and an almost lin-
ear sustained release up to 2 months, have been obtained for double-walled microparticles
composed of PLLA/PLGA and PLGA(80/20)/PLGA(75/25) DWMP [7,12,15,24].
3.3. Viability Assays
To investigate the in vitro toxicity of the unloaded and DOX-loaded NP produced,
mammalian CHO cell lines were exposed to unloaded and DOX-loaded NP for periods of
72 h. Figures 6 and 7 show the effect of DOX-loaded NP on the absolute number of cells
(by direct counting), and on the percentages of dead cells (by means of flow cytometry),
respectively. As a control, an assay was performed in the absence of NP.
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Figure 8. Fluorescence microscopy photographs of CHO cells post-LIVE/DEAD viability/cytotoxicity
assay obtained with no addition of NP (negative control) and with the addition of empty and doxorubicin-
loaded PLGA NP and DWNPs 6:1. Viable cells fluoresce green while doxorubicin flu resces red.
We observed an intense uniform green fluorescence in live cells (due to the presence
of calcein) and a reduction in the number of cells grown in monolayer in the experiments
performed in the prese c of all DOX-loaded NP wh n compared with the assays p r-
form d in the bsence f NP or with unload d NP. No red fluoresc nce is observed in the
xperiments with no addition of NP or with the addition of unloaded NP, s expected,
while red fluorescence is observed in the experiments with DOX-loaded NP. However, this
fluorescence is due to the red color of doxorubicin and not to the presence of dead cells as
they are removed by washing procedures (see Experimental). In all cultures gro n with
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the addition of DOX-loaded NP, cells exhibited a round shape which is an indicator of
cellular death that occurred previous to detachment.
4. Conclusions
DWNPs made of PLGA and PLLA with PLLA/PLGA mass ratios of 2:1, 4:1 and 6:1
loaded with DOX were successfully prepared. The DWNPs produced present a PLGA-rich
core where doxorubicin was mainly solubilized surrounded by a PLLA-rich outer phase.
The DWNPs produced present very low initial burst values and a sustained DOX release
for at least 90 days with release rates decreasing with the increase in the PLLA amount.
Zero-order release kinetics were obtained after day 15. These results support that PLLA
acts as a rate limiting barrier and strongly indicate that a non-drug loaded outer layer can
be effectively used to adjust the drug release rate of DOX from the drug-loaded PLGA core.
A setback can be the smaller volume of the core when compared to the single layer PLGA
NP which yields lower encapsulation capacity and a concomitant lower concentration
of drug released for similar time periods. Nevertheless, the ability to sustain the release
for longer periods is promising for applications that require this kind of strategy. The
unloaded DWNPs produced were used in in vitro tests with CHO cells and demonstrate
that are nontoxic while the DWNPs loaded with the well-known cytotoxic drug DOX
caused a great cellular viability decrease when tested in vitro.
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